Geron Corporation GERN

Geron targets the high end of 2026 RYTELO revenue guidance as community adoption expands. Revenue guidance update and adoption growth point to major positive shifts in financial trajectory and market position.

Geron projects RYTELO revenue near high end of 2026 guidance as community use expands. Strong RYTELO revenue guidance signals major product adoption and financial growth trajectory.

Geron shares rise 14.7% after first RYTELO revenue guidance and narrowed losses. Initial RYTELO revenue guidance plus narrower losses directly shift Geron financial trajectory and investor outlook.

Geron (GERN) issues fresh guidance and earnings that test its undervalued narrative and return the stock to investor focus. Earnings and guidance updates moderately influence Geron Corporation's near-term valuation and market sentiment.

Geron Corporation releases Q2 2026 earnings call transcript covering financial results, operational updates and forward outlook. Quarterly earnings call supplies updated financial metrics and guidance that typically produce moderate short-term market reaction.

Geron Corporation posted strong Q2 2026 revenue growth during its earnings call along with ongoing strategic initiatives. Strong revenue growth and strategic developments point to material positive shifts in financial trajectory and investor outlook.

Geron Corporation held its Q2 2026 earnings call, outlining financial results, operational updates and strategic outlook. Earnings call disclosures typically shape near-term investor views on financial health and pipeline progress without guaranteeing major trajectory shifts.

Geron reported Q2 results with focus on imetelstat development progress, cash position, and upcoming regulatory milestones for its lead blood disorder therapy. Q2 earnings update outlines clinical and financial status that can shift near-term sentiment but does not alter long-term trajectory alone.

Geron Corporation released second quarter 2026 financial results and recent business highlights. Quarterly results and business updates typically affect near-term market perception of performance.

Geron Corporation announces first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes to be presented at EHA 2026. First real-world evidence presentation for RYTELO in LR-MDS at EHA 2026 supports post-approval validation and may moderately boost market sentiment.

Geron (GERN) valuation analyzed after Q1 results and reaffirmed 2026 guidance, highlighting potential upside amid stable financials and long-term revenue projections. Reaffirmed 2026 guidance and Q1 results signal major progress toward commercialization, significantly enhancing market performance outlook.

Geron Corporation (NASDAQ:GERN) reported results, prompting analysts to lift their price targets. Analysts lifting price targets after Geron's report signals significant positive shift in investor sentiment and potential stock trajectory.

Geron Corporation released Q1 2026 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Quarterly earnings summaries influence financial performance views and market sentiment but are balanced by ongoing biotech developments.

Geron Corporation's Q1 earnings call highlights financial results, pipeline progress on imetelstat, cash position, and upcoming milestones amid biotech sector challenges. Q1 earnings call reveals significant updates on financials, clinical advancements, and regulatory paths that could drive GERN stock volatility and long-term valuation.

Geron Corporation (GERN) reported a first-quarter net loss but beat analyst revenue estimates. Q1 loss with revenue beat affects financial performance and short-term investor sentiment without fundamentally altering long-term trajectory.

Geron Corporation reported first quarter 2026 financial results alongside recent business highlights. Quarterly financial results and business highlights moderately influence financial performance and investor sentiment.

Geron Corporation highlighted RYTELO launch progress, 2026 revenue outlook, and Phase 3 myelofibrosis development plans at the Needham Conference. RYTELO launch updates, 2026 revenue projections, and Phase 3 myelofibrosis plans represent significant commercialization and pipeline advancements.

Geron Corporation appoints biopharma veterans to its leadership team as RYTELO therapy gains focus and the company's valuation attracts investor attention. Appointing biopharma veterans bolsters commercialization efforts for RYTELO, a key product, while heightened valuation interest signals strong market momentum.

Geron Corporation outlined RYTELO growth plan, issued $220M-$240M 2026 sales guidance, and highlighted myelofibrosis trial catalyst at Barclays Conference. RYTELO's growth strategy with $220M-$240M 2026 sales forecast and MF trial catalyst indicate major revenue expansion and pipeline advancements.

Geron Corporation (GERN) reported Q4 EPS of (5c). Q4 EPS disclosure affects financial performance and investor sentiment moderately.

Geron Corporation (GERN) investment narrative shifts after analysts cut price target and company unveils new equity incentive plans amid ongoing biotech developments. Target cut lowers expectations while new equity plans introduce potential dilution, moderately influencing financial performance and market sentiment.

Geron Corporation (GERN) 2025 revenue surged to $183.6M, driven by commercial success of RYTELO. Revenue surge to $183.6M from RYTELO success represents a game-changing shift for Geron from development-stage to commercially viable biotech with strong growth prospects.

Geron Corp (GERN) reported strong revenue growth and outlined strategic investments during its Q4 2025 earnings call. Strong revenue growth boosts financials while strategic investments enhance long-term growth prospects.

Geron Corporation summarized its Q4 2025 earnings call, covering financial results, operational updates, and forward guidance. Q4 earnings call summary discloses financial performance, pipeline progress, and strategic outlook that significantly shape investor expectations and stock trajectory.

Geron Corporation reported fourth quarter and full year 2025 financial results alongside recent business highlights. Quarterly and annual financial results with business highlights represent major disclosures that can significantly sway investor sentiment and stock trajectory.

Geron Corporation released highlights from its Q4 earnings call, covering financial results, operational updates, and forward-looking guidance. Q4 earnings call highlights offer moderately noticeable insights into financial performance and pipeline progress without transformative shifts.

Geron Corporation reported Q4 earnings with key financial metrics including net loss, revenue, and EPS figures. Q4 earnings snapshot provides financial updates that moderately affect short-term market sentiment and performance without transformative changes.

Geron Corporation announced 2026 financial goals targeting key milestones in revenue and operations, while TD Cowen lowered its price target on the stock amid mixed analyst views. 2026 financial goals outline long-term strategy but TD Cowen's price target cut introduces short-term market pressure.

Several insiders at Geron Corporation have made significant investments in the company, signaling potential positive developments ahead. This insider buying activity often indicates confidence in the company's future prospects and may influence market sentiment positively. Investors are encouraged to monitor these developments closely as they could reflect underlying optimism about Geron's strategic direction and upcoming initiatives. Insider investments typically indicate strong confidence in the company's future, which can significantly impact market perception and performance.

TD Cowen has maintained a Buy rating for Geron Corporation (GERN) while reducing the price target to $3 ahead of the company's Q4 results. This adjustment reflects the firm's outlook on Geron's performance and market conditions as the earnings report approaches. The price target adjustment indicates a moderately noticeable influence on Geron's financial performance and market sentiment.